RxDoctor Payments Data

Andrew Delemos, MD

Transplant Hepatology · Charlotte, NCNPI 1619098183

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Madrigal Pharmaceuticals at 54.3% of the total.

$44,159in general payments, 2019–2025

Across 31 payments — averaging $1424.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$24K
  • Ipsen Biopharmaceuticals, Inc$14K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • Gilead$323
  • Mallinckrodt Hospital Products Inc.$145
  • Dilon Technologies, Inc.$138
  • plus $298 from 3 others
$1,004,347in research payments, 2019–2025

Across 154 payments — averaging $6521.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$251K
  • Madrigal Pharmaceuticals$249K
  • AbbVie$158K
  • Intercept Pharma Europe Ltd.$117K
  • E.r. Squibb & Sons, L.L.C.$113K
  • Gilead$113K
  • plus $3K from 1 others

What the payments were for

  • Consulting fees$19,78045%
  • Speaking & faculty fees$20,26446%
  • Travel & lodging$2,3765%
  • Food & beverage$1,7384%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant hepatology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$32,709
Medicare patients
209
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir13$311,100
XifaxanRifaximin94$297,114
RezdiffraResmetirom13$52,333
VemlidyTenofovir Alafenamide24$32,413
Envarsus XrTacrolimus32$28,735
Ursodiol104$19,986
Sirolimus16$15,977
LokelmaSodium Zirconium Cyclosilicate18$15,567
EliquisApixaban17$15,104
Mycophenolic AcidMycophenolate Sodium24$13,664
Tacrolimus95$12,800
Entecavir22$8,366
LinzessLinaclotide12$7,366
Mycophenolate Mofetil46$4,750
Cyclosporine ModifiedCyclosporine, Modified11$4,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$323$343,51337 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$98$297,11494 claims
Madrigal PharmaceuticalsRezdiffra$23,975$52,33313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant hepatology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other transplant hepatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →